Identification and functional study of novel oligonucleotides: CpG Seq 13 and CpG Seq 19
In: Immunotherapy, Jg. 13 (2021-05-01), S. 571-585
Online
unknown
Zugriff:
Aim: This study explored new immunoadjuvants with stronger immune activity to enhance therapeutic effects against leukemia. Materials & methods: Whole blood and bone marrow of acute myeloid leukemia (AML) patients and healthy volunteers were collected. Isolated mononuclear cells were treated with two newly designed CpG oligodeoxynucleotides, CpG sequence 13 and 19, and known CpG oligodeoxynucleotides and analyzed via flow cytometry. Results: CpG Seq 13 and 19 possess strong immune activation and enhance the proliferation, degranulation and cytotoxicity of T cells. They also inhibit AML cell proliferation. When CpG Seq 13/19 are combined with anti-OX40 antibodies, the cytotoxicity of T cells on AML cells are further enhanced. Conclusion: CpG Seq 13 and 19 are strong immune adjuvant candidates for AML treatment.
| Titel: |
Identification and functional study of novel oligonucleotides: CpG Seq 13 and CpG Seq 19
|
|---|---|
| Autor/in / Beteiligte Person: | Yang, Nan ; Zhang, Wanggang ; Wang, Xu-Geng ; Zhang, Yang ; Zhang, Hui ; Wang, Jin ; Yao, Huan ; Meng, Shan ; Wang, Yueli ; Liu, Hailing ; Wang, Ting ; Chen, She-Ping ; Chen, Jinqiu ; Lei, Bo |
| Link: | |
| Zeitschrift: | Immunotherapy, Jg. 13 (2021-05-01), S. 571-585 |
| Veröffentlichung: | Future Medicine Ltd, 2021 |
| Medientyp: | unknown |
| ISSN: | 1750-7448 (print) ; 1750-743X (print) |
| DOI: | 10.2217/imt-2019-0197 |
| Schlagwort: |
|
| Sonstiges: |
|